List view / Grid view
Oral peptide-based drugs are set to revolutionise the pharmaceutical industry, overcoming the long-standing challenge of poor bioavailability. Santosh Kulkarni reveals how new breakthroughs in drug discovery and delivery offer the potential for more convenient, effective treatments for a range of conditions – without the need for injections.
Researchers at Mount Sinai have mapped how the 5-HT1A serotonin receptor controls brain signalling – finding a hidden lipid ‘co-pilot’ that could lead to the development of more targeted antidepressants.
Immune resistance is one of cancer’s toughest tricks. By rethinking how we target GPCRs, scientists may finally have a way to modulate it with precision.
Discover how Domain Therapeutics is using its deep knowledge of GPCR biology to create novel therapeutics with the potential to combat inflammatory diseases such as atopic dermatitis, IBD and arthritis.
GPCRs are crucial drug targets, but their complex structures present significant challenges in drug discovery. In this article, Domainex’s Philip Rawlins explores how fragment-based screening and innovative technologies like PoLiPa are helping to overcome these hurdles, with a focus on the Adenosine A2a receptor.
9 January 2025 | By Eurofins DiscoverX
Gain valuable insights into the latest advancements in obesity drug discovery and enhance your research capabilities.
Find out how Confo Therapeutics is overcoming challenges in GPCR drug development to create next-gen therapies for metabolic diseases.
Researchers at the University of Chicago have revealed the complete structure of adhesion GPCRs, uncovering new activation mechanisms that could lead to more targeted drug treatments.
A deep-learning model found metabolites and drugs that could be repurposed for non-addictive and non-opioid options to treat chronic pain.
20 June 2024 | By Eurofins DiscoverX
Join this webinar to discover how GPCR functional, cell-based assays determine off-target effects, reveal safety issues, and define drug mechanism of action to ultimately evaluate the therapeutic potential of candidate molecules.
Drug Target Review's Ria Kakkad spoke with Victoria Goldenshtein at PEGs Europe, about her lab’s novel in vitro library display platform for directed protein evolution called GRIP display – gluing RNA to its proteins.
Japanese researchers now reveal a new way of activating GPCR by triggering shape changes in the intracellular region of the receptor. This new process can help researchers design drugs with fewer or no side effects.
30 January 2023 | By Thermo Fisher Scientific
Watch this webinar to learn how an integrated structural biology workflow can be used to get crucial structural insights on key protein targets that are of therapeutic interest.
US researchers have found that G protein-coupled receptors function in a way not previously known, which suggests untapped potential.
In this exclusive Q&A, Drug Target Review’s Ria Kakkad spoke with Dr Jonathan Javitch, Professor at Columbia University’s Vagelos College of Physicians and Surgeons, about the cutting-edge imaging method single-molecule fluorescence resonance energy transfer (smFRET), used to investigate G protein-coupled receptors (GPCRs).
